NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 383 filers reported holding NEKTAR THERAPEUTICS in Q2 2018. The put-call ratio across all filers is 0.42 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $545,000 | +4.6% | 30,362 | 0.0% | 0.01% | +22.2% |
| Q2 2021 | $521,000 | -14.3% | 30,362 | -0.1% | 0.01% | -18.2% |
| Q1 2021 | $608,000 | -42.0% | 30,389 | -50.7% | 0.01% | -21.4% |
| Q4 2020 | $1,049,000 | -26.8% | 61,684 | -0.4% | 0.01% | -30.0% |
| Q3 2020 | $1,434,000 | 0.0% | 61,932 | 0.0% | 0.02% | 0.0% |
| Q2 2020 | $1,434,000 | +31.4% | 61,932 | +1.3% | 0.02% | +17.6% |
| Q1 2020 | $1,091,000 | +0.6% | 61,137 | +21.7% | 0.02% | -15.0% |
| Q4 2019 | $1,085,000 | +789.3% | 50,247 | +652.8% | 0.02% | +566.7% |
| Q3 2019 | $122,000 | -48.1% | 6,675 | +1.0% | 0.00% | -50.0% |
| Q2 2019 | $235,000 | -73.6% | 6,611 | -75.0% | 0.01% | -62.5% |
| Q1 2019 | $889,000 | +3.7% | 26,456 | +1.5% | 0.02% | +14.3% |
| Q4 2018 | $857,000 | -53.4% | 26,061 | -13.6% | 0.01% | -50.0% |
| Q3 2018 | $1,840,000 | +22.1% | 30,180 | -2.2% | 0.03% | +27.3% |
| Q2 2018 | $1,507,000 | -51.6% | 30,853 | +5.3% | 0.02% | -57.7% |
| Q1 2018 | $3,113,000 | – | 29,293 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 2,000,000 | $67,200,000 | 3.35% |
| First Light Asset Management, LLC | 763,403 | $25,650,000 | 3.33% |
| BRIDGER MANAGEMENT, LLC | 1,238,489 | $41,613,000 | 3.29% |
| Rhenman & Partners Asset Management AB | 734,445 | $24,677,000 | 2.89% |
| BB BIOTECH AG | 2,020,676 | $67,895,000 | 1.71% |
| Gs Investments, Inc. | 54,200 | $1,821,120,000 | 1.43% |
| Artal Group S.A. | 900,000 | $30,240,000 | 1.24% |
| Cormorant Asset Management, LP | 500,000 | $16,800,000 | 1.14% |
| TOBAM | 640,547 | $21,522,000 | 1.09% |
| Bellevue Group AG | 430,026 | $14,449,000 | 0.80% |